Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.

Abstract: Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid, leads to accumulation of the carboxylic acid hydrolysis product in the cell and enables improved or more prolonged enzyme or receptor modulation relative to the unconjugated modulator.

Abstract: Disclosed herein are nanoparticle compositions including an mRNA and a lipid component and methods of using the same. The present invention provides compositions and methods involving lipid-containing nanoparticle compositions to deliver mRNA to cells. In one aspect, the invention provides a nanoparticle composition including (i) a lipid component including a phospholipid (which may or may not be unsaturated), a PEG lipid, a structural lipid, and a compound of formula (I) and (ii) an mRNA encoding a polypeptide of interest.

Abstract: A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

Abstract: The present invention relates to complex particles for delivering nitric oxide, method of producing the particles, and application of the particles, and more particularly, relates to complex particles for delivering nitric oxide and an additional therapeutic reagent.

Abstract: The present disclosure provides compositions and methods for treating an auditory disease in a subject in need thereof comprising administering an effective amount of a gel-based precursor that includes an inner ear-specific therapeutic compound directly into the cochlea of the subject.

Abstract: A formulation includes a carrier agent formed by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, and a biologically active compound associated with the carrier agent.

Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.

Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Abstract: Disclosed are peptide conjugates comprising an active agent, a spacer moiety, and a dimeric collagen hybridizing peptide comprising a first and second collagen hybridizing peptide, a linker; and a branch point, wherein the first and second collagen hybridizing peptides comprise the sequence of at least (GXY)n, wherein G is glycine, wherein X and Y are any amino acid, and wherein n is any number between 3 and 12. Also disclosed are methods of detecting denatured collagen in a sample comprising contacting a composition comprising any one of the disclosed peptide conjugates to a sample, wherein the active agent comprises a therapeutic agent, and detecting the presence or absence of binding of the peptide conjugate to denatured collagen, the presence of binding indicating the presence of denatured collagen in the sample.

Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

Abstract: Pharmaceutical compositions comprising antibody-urease conjugates and substantially free of unconjugated urease are disclosed. These compositions are prepared by a method that does not require chromatographic purification. These pharmaceutical compositions have utility in the treatment of cancer by antibody-directed enzyme prodrug therapy wherein the urease converts endogenous urea into ammonia in situ to induce cytotoxicity.

Abstract: The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.

Abstract: A silybin injection contains silybin, sulfobutyl ether-?-cyclodextrin, an organic solvent for injection and may further contain a co-solvent, a lyophilization proppant, a pH regulator, water for injection and the like.

Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.

Abstract: The invention relates to a viral expression construct and related viral vector and composition and to their use wherein said construct and vector comprise elements a) and b): a) a nucleotide sequence encoding an insulin operably linked to a first promoter, b) a nucleotide sequence encoding a glucokinase operably linked to a second promoter and said viral expression construct and related viral vector comprise at least one of elements c), d) and e): c) the first and the second promoters are positioned in reverse orientation within the expression construct, d) the first and the second promoters are positioned in reverse orientation within the expression construct and are located adjacent to each other and e) the first promoter is a CMV promoter, preferably a mini CMV promoter.

Abstract: Disclosed are nanoparticles comprising an end-modified poly(?-amino ester) and an additive that is a sugar or sugar derivative, such as a sugar, a sugar alcohol or chitosan. The nanoparticles may be used in any field where polymers have been found useful, including in medical fields, particularly in drug delivery. The polymers are useful in delivering a polynucleotide such as DNA, RNA or siRNA, a small molecule or a protein. Also disclosed are compositions comprising said nanoparticles and an active agent, methods for preparing said nanoparticles, said nanoparticles and compositions for use in medicine, and in vitro methods using said nanoparticles and compositions.

Abstract: Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

Abstract: The present invention relates to compositions and methods for the inhibition of the infectivity of a herpesvirus. In certain embodiments, the compositions and methods provide a CRISPR-associated peptide and a guide nucleic acid, which induce the mutation of herpesvirus genome, thereby inhibiting the infectivity of the herpesvirus. Further disclosed are Cas peptides including Cas9 or a variant thereof comprising one or more point mutations relative to wildtype Streptococcus pyogenes Cas 9 (spCas9), and Cpf1 or a variant thereof.

Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion DA and DB).

Abstract: Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

Abstract: The present invention relates to the field of diagnostics and, more in particular, to MRI activatable contrast agents and compositions thereof for the detection of nuclease activity, wherein said nuclease activity is caused by microbial infection or by nuclease activity related to cancer, particularly colon cancer or pancreatic cancer. Activatable contrast agents for MRI have been developed, wherein the oligonucleotide is flanked by a paramagnetic and a superparamagnetic agent, and thus providing magnetic quenching. Moreover, the oligonucleotide has regions that confer resistance to mammalian endonucleases and sensitivity to microbial endonucleases. When the activatable contrast agent of the invention is in the presence of microbial nuclease activity or a tumour cell nuclease activity, the oligonucleotide is cleaved, agents are unquenched, and the signal derived from the activated contrast agent is detected by MRI.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: The present invention relates to a device and a method for cleaning and sterilizing a filling valve of a beverage filling system for filling a container with a filling product. The device includes a cap for closing a filling product outlet of the filling valve during the cleaning and sterilization, and a valve for opening and closing the through-opening. The cap has a through-opening for discharging sterilization medium during the sterilization. The valve includes a shape-memory material for switching the valve between an open and closed position at a predetermined temperature.

Abstract: A method of sterilizing an article such as a flexible endoscope is performed in a sterilization chamber. A vacuum is applied in the sterilization chamber while the article is contained in the sterilization chamber. A sterilant is then introduced into the sterilization chamber. The pressure within the sterilization chamber is incrementally increased to provide a step-wise transition from a high vacuum state to atmospheric pressure. The article is thereby sterilized.

Abstract: A method and apparatus for extending the range and effectiveness of scents is disclosed. The apparatus includes a container which contains a scented substance and a controllable heat source which is used to heat the scented substance to a vaporized state. A controllable air supply is then used to blow the vaporized scent into the environment. The apparatus is controlled by an electronic control unit.

Abstract: In response to user interaction, a signal is generated from a control element of a sample diffuser assembly. The sample diffuser assembly comprises a sample container, wherein the sample container is configured to receive a sample to be diffused; a motor operative to assist in diffusing the sample at a selectable transformation rate; a light source, wherein the light source comprises an AC lamp; and control circuitry operatively coupled to the motor and the light source. A set of signals is generated, via the control circuitry in response to the signal generated by the control element, wherein the set of signals simultaneously control the light intensity of the AC lamp based on the transformation rate produced by the motor to diffuse the sample in the sample container.

Abstract: A water permeability-imparting agent containing an alkylene oxide adduct (A) of a polyvalent active hydrogen compound represented by Formula (1): R—[O(A1O)m—(CH2CH2O)n—H]1 ??(1) wherein R represents a residue, after removal of all active hydrogen, of the polyvalent active hydrogen compound; A1O represents a C2 to C4 alkyleneoxy group; m represents an average addition mole number of A1O and is a number of 4 to 50; n represents an average addition mole number of CH2CH2O; and 1 represents a valence and is an integer of 3 to 6, and an average addition mole number ratio between A1O and CH2CH2O in Formula (1), n/m, is 0 to 0.5.

Abstract: A wound covering is provided that comprises a substrate and vitamin D, or analogues or metabolites thereof, embedded in the substrate. Methods of making a wound covering are also provided and include the steps of providing a solution that includes a polymer; adding vitamin D, or analogues or metabolites thereof, to the solution to form a mixture; and forming one or more fibers from the mixture that are then embedded with the vitamin D, or analogues or metabolites thereof. Methods of treating a subject are further provided and include the step of applying a wound covering including one or more fibers embedded with vitamin D, or analogues or metabolites thereof, to a site on a subject.

Abstract: A system for managing female incontinence includes a body of biocompatible material configured to fit between the labia minora and the vestibule floor, the body having a surface configured to occlude the urethral meatus, an adhesive carried on at least a first portion of the surface and configured to provide a sealing engagement between the body and the urethral meatus, and a substance carried by at least one of the body and the adhesive and configured for controlling the odor of the general vaginal-urethral area of a female.

Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Abstract: This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic ?-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures.

Abstract: An antiseptic composition for use as bone cement, in particular an antiseptic polymethylmethacrylate bone cement. The composition can be cured and comprises a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid, whereby the salt of the monoperoxy dicarboxylic acid can be dissolved from the composition in the presence of water. Preferably, the salt of the monoperoxy dicarboxylic acid in the composition is used in the form of a powder, whereby the powder has a mean particle size of not more than 250 ?m. Preferably, the salt of the monoperoxy dicarboxylic acid, in solution at room temperature, is not degraded within 5 min by the catalase enzyme.

Abstract: A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The elastomeric adhesive composition may be a hydro-colloid-adhesive composition comprising, hydrocolloid and elastomer. The dressing composition releases nitric oxide, which may have beneficial effects, when used on wounds or moist skin, with a substantially constant release rate over a long period of time. A dressing including a layer of the dressing composition has a backing layer and may have a release liner removably attached to the skin-contacting surface of the dressing layer.

Abstract: Embodiments of this technology may include an apparatus for drying tissue. The apparatus may include human donor tissue placed in contact with and between at least two layers of backing material. This tissue and backing layer may then be restrained by two plates. This tissue may be amniotic tissue. The backing layer may include woven or nonwoven material. This backing layer may be wetted with a saline solution. At least one of the plates of the tissue drying apparatus may be perforated. The tissue assembly along with the plates may then be placed inside a chamber configured to receive the plates and tissue assembly. The chamber may be configured so that gas can be forced into the chamber with the gas flow going around the plates and the tissue assembly.

Abstract: A method of preparing a porous bone substitute is provided. The method includes preparing a ceramic paste including calcium phosphate-based ceramics, preparing a molded article formed of the ceramic paste based on a 3D rapid prototyping method, drying the molded article, and sintering the dried molded article.

Abstract: A method of fabricating a scaffold for tissue engineering that includes a frame structure including one of poly-D-lactic acid and poly-L-lactic acid and a coating layer formed on a surface of the frame structure and including a lactic acid-glycolic acid copolymer. The method includes mixing a first granular porous substance including one of poly-D-lactic acid and poly-L-lactic acid with a second granular porous substance including the lactic acid-glycolic acid copolymer to prepare a mixture, and pressurizing and heating the mixture in a mold. In the heating, the mixture is heated to a temperature greater than or equal to the melting point of the lactic acid-glycolic acid copolymer and less than the melting point of one of poly-D-lactic acid and poly-L-lactic acid.

Abstract: There is provided a method for preparing a dense hydrogel comprising an at least partially gelled hydrogel, placing the at least partially gelled hydrogel in fluid communication with an end of a capillary, and driving the at least partially gelled hydrogel into the capillary to form a dense hydrogel. There is also provided a system for preparing the dense hydrogel comprising a capillary having a bore; and a driver in communication with an end of the capillary for driving an at least partially gelled hydrogel into the bore of the capillary to form a dense hydrogel.

Abstract: Compositions of matter comprising decellularized omentum are disclosed. The compositions may be scaffolds, hydrogels or hydrogel precursor compositions. Methods of generating the compositions are disclosed as well as uses thereof.

Abstract: A prosthetic implant with improved properties, suitable for implantation to the human body, comprising a composite comprising a base material and a plurality of additives, wherein the additives are selected from radiolucent additives and/or hyperechoic additives; or wherein the additives are selected to reduce the solvent concentration by between 5%-95%; or wherein the additives are selected to increase the elastic modulus by more than 20%; or wherein the additives are selected for combining these effects.

Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Abstract: The present disclosure relates to methods for embedding drug molecules into medical catheters, tubes, and other medical devices. The catheter, tube, or other medical device is capable of releasing drugs for extended periods of time. Drugs can be loaded into the wall thereof through diffusion from a solution, e.g., loading solution. A counterintuitive approach of using undissolved drug particulates in the solution is employed in some embodiments. The drug in the wall of the device and in the solution (which when stored may be referred to as a storage solution) can be in dynamic equilibrium, yielding stable and easy-to-manufacture products. Heat can be used to significantly speed up the drug loading.

Abstract: There is provided a process for producing a medical, material that retains the properties which are inherent in a polyanionic polysaccharide being a raw material, that has a high level of safety because there is no need to use a chemical crosslinking agent, and that has moderate strength and flexibility. The present invention is a process for producing a medical material, the process including a step of dispersing a powder or a granular product of a first polyanionic polysaccharide, the first polyanionic polysaccharide water-insolubilized with a treatment liquid containing a first acid anhydride, in an aqueous solution of a water-soluble salt of a second polyanionic polysaccharide, thereby obtaining a dispersion liquid, a step of drying the dispersion liquid obtained, thereby obtaining a dried film, and a step of water-insolubilizing the dried film obtained with a treatment liquid containing a second acid anhydride, thereby obtaining the medical material.

Abstract: A continuously hollow device for the transfer of fluids to the human body is provided, which is made in a nanomaterial derived from latex, which chemical composition in based primarily on fats, waxes and several gummy resins obtained from cytoplasm of lactic cells. This biochemically modified material is capable of adjusting its outer and inner diameter, i.e. it enlarges or shrinks according to the needs of the patient. The device corresponds to a needle or the like (catheter), which allows to have a very small diameter so as to be inserted in the patient (minimally invasive procedure) and after a physical excitation of such nanomaterial, it can be extended once inserted in the body so as to allow the intake or discharge of fluids to or from the body through a catheter, probe or the like.

Abstract: A method for preparing a laminate coronary stent comprising: providing a stent framework; and depositing a plurality of layers on said stent framework to form said laminate coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer.

Abstract: An implantable device comprising a core portion and a capsule encapsulating the core portion, said capsule having an outer surface, wherein at least a portion of the outer surface comprises gold.

Abstract: A fluid management system including a pass-through fluid volume measurement system to provide continuous measurement of fluid returned from a surgical site during transit to a waste collection system. The pass-through fluid volume measurement system eliminates the need to physically replace full fluid collection containers during the medical procedure with new, empty fluid collection containers.

Abstract: Containers for collecting fluid are provided that include a reservoir comprising a plurality of panels enclosing an interior, side panels of the reservoir are movable from an expanded position towards to a compressed position and biased to the expanded position for generating a vacuum within the interior. An elongate housing extends along a top side of the reservoir including a passage extending between proximal and distal ends thereof and communicating with the interior of the reservoir. An elongate member extends through the housing including a distal extension, a proximal extension, and a lumen extending therebetween. One-way valves are coupled to the distal and proximal extensions for permitting fluid flow proximally from the distal extension into the interior of the reservoir via and permitting fluid flow proximally from the proximal extension while preventing fluid flow distally out the distal extension and distally into the proximal extension and lumen.

Abstract: A system and apparatus for the collection of serous or serosanguinous fluid from a percutaneous site after surgery. A pump unit with one or more pumps or powered sources provide continuous negative pressure suction to draw fluid from the percutaneous site and pumps the fluid into disposable reservoirs with one-way valves that are easy to handle while maintaining sterility and a seal to prevent the loss of vacuum. Air is continuously removed from the reservoirs. Measurement and analysis of the output is performed automatically.